New research on commonly prescribed blood thinners shows that rivaroxaban, known better by its brand name Xarelto, was associated with a significantly higher risk of bleeding complications. To provide much-needed transparency for patients, U-M researchers tested three popular medications prescribed to treat blood clots or atrial fibrillation. Read about their findings in this article from the Institute for Healthcare Policy and Innovation.
Join us Sept. 14 at the U-M Golf Course for the 2024 Alumni Territory Homecoming Tailgate!